An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPD). Several phenotypic manifestations, i.e. polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis, can be associated with the same mutation. We generated JAK2-V617F transgenic mice using a human JAK2 gene with the sequences encoding the kinase domain placed in the inverse orientation and flanked by antiparallel loxP sites. Crossing mice of one transgenic line (FF1) with transgenic mice expressing Cre-recombinase under the control of the hematopoiesis specific Vav promoter led to expression of JAK2-V617F that was lower than the endogenous wild type Jak2. These mice developed a phenotype resembling ET with strongly elevated platelet counts and moderate neutrophilia. Induction of the JAK2-V617F transgene with the interferon-inducible MxCre resulted in expression of JAK2-V617F approximately equal to wild type Jak2 and a PV-like phenotype with increased hemoglobin, thrombocytosis and neutrophilia. Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis. These data are consistent with the hypothesis that the ratio of mutant to wild type JAK2 is critical for the phenotypic manifestation. A similar correlation was also found in patients with MPD.
Introduction
An acquired somatic mutation in the JAK2 gene resulting in a valine to phenylalanine substitution at position 617 (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPD). [1] [2] [3] [4] This discovery suggested that the presence of the JAK2-V617F mutation could represent the primary causative lesion in MPD. While the JAK2-V617F mutation is found in approximately 95% of patients with polycythemia vera (PV), it is also detectable in about 50% of patient with primary myelofibrosis (PMF) and essential thrombocythemia (ET). 2, 5 It remains unclear how the identical JAK2-V617F mutation can cause three distinct clinical entities. In patients with PV and PMF, but only rarely in ET, the JAK2-V617F mutation progresses from the heterozygous state to homozygosity through mitotic recombination of the distal part of chromosome 9p. 4, 6 Retroviral transduction of mouse bone marrow cells followed by transplantation into lethally irradiated mice demonstrated that the expression of Jak2-V617F is sufficient to induce a phenotype resembling PV. 1, [7] [8] [9] [10] These mice showed massive increase in hematocrit and hemoglobin concentration and a variable degree of neutrophilia. In contrast to patients with PV, the platelet numbers in these mice remained normal or were even decreased. After several months some of the mice also developed myelofibrosis.
The phenotype was not affected when bone marrow from donor mice deficient for the Src family kinases Lyn, Hck and Fgr were used, but was dependent on the presence of Stat5. 10, 11 To establish a mouse model for MPD we generated bacterial artificial chromosome (BAC) transgenic mice that express the human JAK2-V617F driven by the JAK2 promoter. A constitutively active version and an inducible version of the BAC-transgene were constructed. Transgenic mice that display ET or PV phenotypes have been obtained in the C57BL/6 background.
Materials and Methods

Transgenic mice
The human JAK2-V617F transgene was constructed using the BAC CTD2025A15
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From and Cell Biology, Singapore) and the ampicillin cassette was subsequently removed by induction of Flpe recombinase. 13 For the inducible Flip-Flop transgene, the construct was modified by inserting a lox66 site into intron 12 and a lox71 site after the polyadenylation signal. 14 The segment between the loxP sites was then inverted by restriction digest and the new construct was inserted into the BAC as before.
For oocyte injection, BAC DNA was digested with NotI to remove the vector and purified by over a Sepharose CL4b column (Amersham Biosciences, Piscataway, NJ).
Genotyping of transgenic Flip-Flop mice was performed using the human JAK2-specific primers GAGCAAGCTTTCTCACAAGC and AATTCTGCCCACTTTGGTGC that amplify a 530 bp fragment. The number of integrated transgene copies was determined by real-time PCR with the primers GTGGCAGCAACAGAGCCTATC and GGAGCTTCAGCACCTCGAGAT for human JAK2 and TGGCAGCAGCAGAACCTACA and GGAGCTTCAGCCCCACG for mouse Jak2.
MxCre mice were genotyped using the primers AGGTGTAGAGAAGGCACTTAGC and CTAATCGCCATCTTCCAGCAGG that amplify a 300 bp fragment. Cre expression was induced in MxCre;FF1 double transgenic mice by intraperitoneal injection of 300µg polyinosine-polycytosine (pIpC) 3 times every second day. VavCre mice were kindly provided by Dr. Dimitris Kioussis (National Institute for Medical Research, London, UK) and genotyped using the primers CTCTGACAGATGCCAGGACA and TGATTTCAGGGATGGACACA (500 bp fragment). The integration site of the transgene in the FF1 strain was localized by fluorescence in situ hybridization using the Institute Center for Genotyping and Analysis, Boston, MA). All mice used in this study were kept under specific pathogen-free conditions and in accordance to Swiss federal regulations.
Retroviral transduction and bone marrow transplantation
Human JAK2 cDNA (kindly provided by Dr. Jan Cools, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium) or human JAK2-V617F cDNA was cloned into the retroviral vector pMSCV-IRES GFP. An equivalent plasmid containing mouse Jak2-V617F was kindly provided by Dr. D. Gary Gilliland (Brigham and Women's Hospital, Boston, MA). Bone marrow transplantation was performed as previously described.
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Blood and tissue analysis
Blood counts were determined on an Advia 120 Hematology Analyzer using the "Multispecies Software" (Bayer, Leverkusen, Germany). Plasma erythropoietin and thrombopoietin levels were measured with the Quantikine Mouse/Rat Epo or Tpo Immunoassay kit (R&D Systems, Abingdon, UK). For histopathological analysis tissue specimen were fixed in 10% neutral buffered formalin and embedded in paraffin. Paraffin sections (4µm) were stained with hematoxylin and eosin (H&E) or Gömöri (reticulin fibers). Images were taken using an Axio Imager A1 microscope equipped with a Plan Apochromat objective (63x, numerical aperture 1.4, oil) and a mounted Axio Cam HR digital camera (all Zeiss, Jena, Germany). The software for image acquisition was AxioVision Rel. 4.6.
Hematopoietic progenitor assays and flow cytometry
Methylcellulose media were purchased from Stem-Alpha (St Genis L'Argentière, France) and 2x10 4 
Real-time PCR , allelic ratio and Southern blot analysis
Expression analysis in mice was performed with Power SYBR Green PCR Master mix on a 7500 Fast machine (Applied Biosystems) using the following primers:
TCACCAACATTACAGAGGCCTACTC and GCCAAGGCTTTCATTAAATATCAAA (human JAK2), CCACGGCCCAATATCAATG and CCCGCCTTCTTTAGTTTGCTA (mouse Jak2). Results were confirmed with the Taqman Gene Expression assays Hs01078117_m1 for human JAK2 and Mm01208495_m1 for mouse Jak2 (Applied Biosystems). Ratios of human and mouse Jak2 were assessed in the "Absolute Quantification" setup with standard curves made from linearized pMSCV-IRES GFP plasmids containing either human JAK2 or mouse Jak2. Total JAK2 expression in patients was assessed using the Taqman Gene Expression assays Hs01078124_m1 (JAK2) and Hs02338565_gH (human RPL19). Primers and probes for the housekeeping genes GUSB and B2M were described elsewhere. 16 The primers for mouse Gusb were ATAAGACGCATCAGAAGCCG and ACTCCTCACTGAACATGCGA. Expression of mutant and wild type JAK2 and quantification of allelic ratios in granulocyte DNA from patients was done as previously described. 17, 18 For Southern blot analysis, 5 µg genomic DNA was digested with XbaI and fragments blotted onto a Hybond N+ membrane (Amersham Biosciences) were hybridized with a radiolabeled probe generated by PCR with the primers TTCTCGTCTCCACAGACACA and ATTCTGCCTCTGCAGACCAC.
Radioactive bands were quantified on a Molecular Imager FX (BioRad, Hercules, CA).
Transgene copy numbers were measured by real time PCR with the primers GTGGCAGCAACAGAGCCTATC and GGAGCTTCAGCACCTCGAGAT for human JAK2 and TGGCAGCAGCAGAACCTACA and GGAGCTTCAGCCCCACG for mouse Jak2. To determine the number of transgene copies in the native orientation, the primers GCTGCAGCACAGAGATTAAATAGC and TGGATCGACATAACTTCGTATAATGTATG were used, which are located 5' and 3' of the lox71 site ( Figure 1 ). Real-time PCR efficiency with these primers was very similar to the efficiency of copy number primers that were used to determine total human JAK2. Therefore, the number of actively rearranged transgene copies could be calculated and results were comparable to Southern blot analysis. 
Patients
Results
Generation of JAK2-V617 transgenic mice
To study the in vivo role of JAK2-V617F in the pathogenesis of MPD, we made BACtransgenic mice that express the human JAK2-V617F driven by the endogenous human JAK2 promoter. The 190 kb BAC clone contained 96 kb of JAK2 5'-upstream region that does not include other known genes, as well as exons 1-12 and a part of intron 12 of the human JAK2 gene ( Figure 1A ). Using homologous recombination in bacteria we added the missing part of intron 12 including the splice acceptor and a cDNA fragment consisting of exons 13 to 25 followed by an SV40-derived polyadenylation signal. 13 The construct was prepared in two versions, one containing the V617F mutation (VF) and a control construct with wild type sequence (WT Figure   1C ). We determined the integration site by restriction digest and circular ligation followed by PCR and sequencing, and found that the integration occurred at a locus near the centromere that does not contain any known genes (data not shown). A combination of transgene activation and copy number reduction can result when Cre-recombinase is expressed ( Figure 1D ). Ultimately, a single copy of the transgene in the active orientation will result form this process, provided that all transgene copies were in the head to tail orientation and that the Cre-recombinase reaction was allowed to proceed to completion.
Polycythemia vera-or essential thrombocythemia-like phenotype in JAK2-V617F transgenic mice
To induce recombination and activation of the FF transgene we crossed the FF mice with Figure 2 and Supplemental Table S1 . At 10 weeks, VavCre;FF1 mice showed normal hemoglobin, slight increase in neutrophils, and marked thrombocytosis, resembling ET (Figure 2A ). At 10 weeks after pIpC induction, MxCre;FF1 displayed a PV-like phenotype with elevated hemoglobin, thrombocytosis and neutrophilia ( Figure   2A ). A considerable phenotypic variability, in particular in respect to platelets and neutrophils, was observed. The increase in erythrocyte numbers was accompanied by a slight decrease in mean corpuscular volume (Supplemental Table S1 ). In comparison, MxCre to obtain MxCre;FF2 mice. We did not observe any significant abnormalities in blood counts after pIpC induction and found that the expression levels of the transgene were low (data not shown). We therefore focused our analysis on the FF1 strain. Tpo plasma concentrations at 20 weeks in both MxCre;FF1 and VavCre;FF1 mice showed no significant differences from normal controls, although a trend to lower values was noted, particularly in MxCre;FF1 mice ( Figure 2D ). Epo plasma levels were slightly suppressed in MxCre;FF1 mice, as frequently observed in PV patients ( Figure 2D ). The liver showed extramedullary hematopoiesis with highly atypical megakaryocytes, but islands with myelopoiesis and erythropoiesis could also be found ( Figure 3F ).
Hematopoietic cells including megakaryocytes, were also found in the lung ( Figure 3G ). The ratios between the expression levels of mutant JAK2-V617F and wild type Jak2
correlate with disease phenotype
To determine whether the phenotypic differences between VavCre;FF1 and MxCre;FF1 mice might be due to differences in the expression levels of the human JAK2-V617F, we quantified the expression of the transgenic JAK2-V617F and endogenous Jak2 mRNA by real-time PCR ( Figure 5A ). To detect solely transcripts of the flipped FF1 transgene, oligonucleotides located in exons 12 and 13 human JAK2 were used that do not prime in mouse Jak2. In addition, mouse specific primers were used to assess expression of endogenous Jak2. The expression values were normalized to the mRNA for β-glucuronidase (Gusb). VavCre;FF1 mice showed JAK2-V617F expression in hematopoietic tissues ( Figure 5A, upper panel) . In addition, we also detected transgene expression in lung and at low levels in liver and testis. The MxCre;FF1 mice showed a wide distribution of transgene expression. The presence of hematopoietic cells might contribute to the relatively high expression levels observed in the lung ( Figure 3G ). The endogenous mouse Jak2 was expressed in all tissues examined and no major differences were found between VavCre;FF1 and MxCre;FF1 mice ( Figure 5A , lower panel). We next compared the expression of human JAK2-V617F and mouse Jak2 in the bone marrow of double transgenic mice to mice transplanted with bone marrow retrovirally transduced with human JAK2-V617F ( Figure 5B ). VavCre;FF1 mice showed the lowest expression of JAK2-V617F, followed by MxCre;FF1, and the highest expression levels To determine the ratio of JAK2-V617F to wild type Jak2, we developed a quantification assay that normalizes for differences in the amplification efficiencies between the primers used for human and mouse JAK2 (Figure 5B, right) . For this purpose, standard curves were generated from plasmids that contained either human JAK2 or mouse Jak2, but were otherwise identical. Transgene expression was less than half of endogenous Jak2 in bone marrow of VavCre;FF1 mice. In MxCre;FF1 mice the expression of mutant JAK2 was comparable to wild type Jak2, whereas in retrovirally transduced bone marrow the mutant JAK2 was around 3-fold higher than wild type Jak2 ( Figure 5B, right) . A similar pattern, but slightly lower ratios were also seen in spleen and in peripheral blood granulocytes (not shown). Since the expression levels of JAK2-V617F could depend on the number of functionally rearranged copies of the FF1 transgene, we performed Southern blot analysis to determine the ratio of flipped versus native form of the transgene ( Figure 5C ). In the same samples we measured the transgene copy number by real time PCR to determine the rate of excision by Cre-recombinase. Cre activity is expected to generate both active rearrangement and copy number reduction by excision ( Figure 1D ). In bone marrow of VavCre;FF1 mice we found more than 80% of the transgene to be flipped into the active configuration, but at the same time the number of transgene copies was reduced to an average of 2 ( Figure 5C Figure S2) . We confirmed the correlation between flipped transgene copies and ratio of human JAK2-V617F to mouse Jak2 ( Figure 5D, left panel) .
Furthermore, the hemoglobin concentration correlated with the ratio of human JAK2-V617F to mouse Jak2 ( Figure 5D, right panel) . Two outliers showed unexpectedly low . In PV patients we detected lower wild type JAK2 mRNA levels than in ET patients or healthy controls ( Figure 6B , right). The cause of the inter-individual differences in total JAK2 expression levels ( Figure 6A ) is currently unknown. The amplitudes of these differences, but not the overall conclusions, are influenced by the choice of gene for normalization (Supplemental Figure S3) . A strong linear correlation between the percentage of JAK2-V617F mRNA and the allelic ratio of JAK2-V617F in genomic DNA was noted ( Figure 6C ), similar to a previous study. 17 Thus, despite the inter-individual variations in the total expression levels, the relative expression of the mutant versus wild type JAK2 mRNA in humans appears to depend primarily on the percentage of chromosomes carrying the JAK2-V617F mutation (%T). Since the %T in ET patients are on average lower that in PV and PMF, ET patients also displayed lower ratios of mutant/wild type JAK2 mRNA than PV patients ( Figure 6D ), reminiscent of the pattern found in our transgenic mice ( Figure 5B ). with the number of actively rearranged transgene copies and the ratio of expression levels of transgenic JAK2-V617F in respect to the endogenous mouse Jak2. The transgenic mice displayed clearly lower expression levels than bone marrow cells retrovirally transduced with JAK2-V617F. These results suggest that the hematopoietic lineages show differences in responsiveness to the presence of the mutated JAK2-V617F, with megakaryopoiesis being most sensitive, followed by granulopoiesis and erythropoiesis.
High levels of JAK2-V617F appear to be inhibitory to megakaryopoiesis, as illustrated by normal or decreased platelet counts in the retroviral models. In this context it is noteworthy that in PV patients a negative correlation of JAK2-V617F expression level with platelet counts, but a positive correlation with hemoglobin and granulocyte counts has been reported. 17, 25, 26 In addition, ET patients on average display higher platelet levels than PV patients, 17 which is reflected in our VavCre;FF1 mice that show higher platelet levels than MxCre;FF1 mice. Jak2 protein was found to function as a chaperone promoting cell surface localization of the thrombopoietin receptor Mpl, 27 Ubiquitous high level of JAK2-V617F transgene expression might be lethal, as we were unable to establish a VF transgenic line that exhibits a MPD phenotype. Two founder mice died before giving rise to offspring, both with a clearly enlarged spleen. The only transgenic line we obtained (VF1) showed low expression (ratio mutant/wild type JAK2 mRNA = 0.32±0.02 in bone marrow, n = 5) and appears to have been selected for minimal phenotype (Supplemental Table S1 ). Consistently, no germ line mutations in JAK2 have been reported to date in human familial MPD. The inducible BAC construct allowed us to establish the transgenic line FF1 that exhibits either an ET or a PV phenotype, depending on the mode of transgene activation. Because nine copies of the transgene are present in FF1 mice, Cre mediated excision can result in activation and/or excision of the transgene ( Figure 1D ). The numbers of actively rearranged copies of the transgene correlated with JAK2-V617F expression levels. Dependence of expression on transgene copy numbers has been found in many BAC transgenes and is considered an advantage over the use of classical small transgenic constructs. [32] [33] [34] The Vav promoter used in our VavCre mice has been shown to display variable expression efficiency in erythroid cells. 20 also displayed a trend towards lower hemoglobin ( Figure 5D and Supplemental Table   S1 ). Conversely MxCre;FF1 mice that received a single dose of pIpC showed the highest number of actively rearranged transgene copies and the highest hemoglobin levels.
Although this data is based on a relatively small number of mice, it suggests that variations in phenotype primarily depend on the number of actively rearranged transgene copies, rather than the lineage specificity of the promoter driving Cre expression. The
Vav promoter is already active in the fetal liver. 35 VavCre;FF1 mice therefore could be expected to show thrombocytosis at a young age. However, we found that platelet levels at 5 weeks in these mice were only slightly elevated, and a marked increase was observed only at later time points ( Figure 2B ). The reason for the slow disease progression is currently unknown.
Quantification of JAK2-V617F expression using two different real time PCR approaches
showed a strong correlation with phenotype ( Figure 5 ). The ∆∆CT method allows to reliably determining the relative expression of the human and mouse JAK2, but the absolute levels cannot be directly compared, because the amplification efficiency of the human and mouse primer pairs is likely to vary. We therefore established standard curves to derive the ratios of human/mouse JAK2 presented in Figure 5B , which confirmed the differences between the two transgenic strains and the retroviral model. A dependence of the platelet phenotype on Jak2-V617F expression levels was also noted in one of the retroviral mouse models, in which a subgroup of secondary recipients of bone marrow transplantation showed a 1.6-fold increase in platelet numbers 2 weeks after transplantation. 7 At 3 and 4 weeks the platelet levels were equal to the controls. This subgroup of mice showed a lower ratio of mutant/wild type Jak2 mRNA (average 2.8-fold) than other transplanted mice with normal platelet counts (average 8.2-fold). These ratios are higher that those observed in our mice. Despite showing a ratio of mutant/wild type mRNA of 3, our mice transplanted with retrovirally transduced bone marrow expressing JAK2-V617F showed normal platelet numbers (Figure 2A ). Since the retroviral constructs as well as the methods used for quantification were different, we
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Thus, in mouse models the presence of the JAK2-V617F is sufficient to generate the full range of MPD phenotypes. The phenotypic variation appears to depend on the ratio of mutant/wild type JAK2 mRNA. A contribution of genetic background on the phenotypic expression is unlikely, since our MxCre;FF1 mice were >98% C57BL/6 and showed ET or PV phenotypes depending on the scheme of transgene activation, i.e. number of pIpC injections ( Figure 5D and Supplemental Table S1 ). Clearly, the ratio of mutant/wild type JAK2 mRNA is only a surrogate parameter and the expression and phosphorylation status of the mutant and wild type Jak2 proteins in hematopoietic progenitors need to be monitored. Furthermore, in some mice the blood counts did not correlate with transgene expression ( Figure 5D ), suggesting that additional unknown factors, possibly somatic mutations, may modify the phenotype.
Increased bone marrow fiber content was more pronounced in VavCre;FF1 mice than in MxCre;FF1 mice and appears to correlate better with the extent of thrombocytosis than with the mutant/wild type mRNA ratio, i.e. VavCre;FF1 mice showed dilated sinusoids and more pronounced fibrosis despite a low mutant/wild type mRNA ratio. In contrast, a high mutant/wild type mRNA ratio was detected in PMF patients. In the retroviral models, megakaryocyte maturation defects have been observed that are thought to be responsible for the normal or low platelet counts possibly through an altered chaperone function of Jak2-V617F protein. Fibrosis in these mice is likely related to the elevated megakaryocyte mass in the bone marrow.
In ET patients we also observed lower expression levels of JAK2-V617F than in PV ( Figure 6 ). However, a logarithmic scale was used to show the differences in human patients, whereas a linear scale was used for the differences in mice (Figure 5 ), reflecting a much wider range of ratios present in the patients. In contrast to our transgenic mice that display graded levels of JAK2-V617F with wild type JAK2 being present in every cell, each individual blood cell from patients with MPD can only be homozygous or heterozygous for the mutation, or normal. Thus, the resemblance of the plots is due to the
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fact that a mixture of granulocytes with wild type JAK2 and granulocytes heterozygous for JAK2-V617F are present in ET, whereas patients with PV and PMF frequently have additional cells homozygous for JAK2-V617F. 4, 37, 38 Therefore, the molecular mechanism determining the phenotype in humans may be more complex than in our mouse model and appears to be linked to the transition of the JAK2-V617F mutation to homozygosity.
A subset of PV patients that lack cells with homozygous JAK2-V617F was recently described, suggesting that alternative mechanisms to cause expansion of the erythroid lineage exist in PV patients. 26 Similarly, patients with mutations in exon 12 of JAK2 generally do not progress to homozygosity.
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The FF1 transgenic mouse model offers several advantages over the previously reported retroviral models using bone marrow transplantation: our transgenic mice exhibit bi-or tri-lineage disease including thrombocytosis, as observed in human patients with ET and PV. The expression levels of the JAK2-V617F transgene are comparable to the endogenous Jak2, in contrast to the very high expression levels observed in most of the retroviral models. In addition, we show that the human JAK2-V617F causes MPD in mice, which will be important for testing Jak2 inhibitors as potential therapeutic agents. and controls (n = 6) were seeded in methylcellulose containing mouse IL-3, human IL-6 and IL-9, mouse stem cell factor and human erythropoietin (A), or in collagen media containing thrombopoietin, mouse IL-3 and human IL-6 (B). Colonies were enumerated at day 8. Prior to counting, collagen cultures were fixed and stained for acetyl cholinesterase activity to visualize megakaryocytes. CFU-GEMM, colony forming unitgranulocyte, erythroid, macrophage, megakaryocyte; CFU-GM, sum of colony forming unit-granulocyte, colony forming unit-macrophage and colony forming unit-granulocyte, macrophage; BFU-E, burst forming unit-erythroid. Spleens of double transgenic mice showed marked increase in hematopoietic progenitors. For statistical analysis, we performed pairwise Mann-Whitney tests. Asterisks indicate statistically significant differences (P < 0.05; in A for all colony types) . A slight decrease in expression of mouse Jak2 was noted in MxCre;FF1 compared to controls (middle panel, P = 0.04), whereas no significant difference was found between VavCre;FF1 and MxCre;FF1. The ratios between human JAK2-V617F and mouse Jak2 in bone marrow were calculated from the absolute expression values of human JAK2 and mouse Jak2 that were determined by comparison with standard curves set up from purified plasmids containing human JAK2 or mouse Jak2. Significant differences between VavCre;FF1 and MxCre;FF1 (P = 0.0003) and between MxCre;FF1 and pMSCV-hV617F (P = 0.0007) were noted. All significant differences (P < 0.05) are marked by asterisks. (C) Assessment of Cre-mediated recombination by Southern blot analysis and copy number determination by real-time PCR. DNA from bone marrow and spleen cells was digested with XbaI and the Southern blots of DNA fragments separated by electrophoresis were visualized with a 32 P-labeled human JAK2 cDNA probe (thick solid line). The scheme below shows the position of XbaI restriction sites and of the probe. The expected fragments sizes are 800 bp for the native configuration and 3'500 bp for the flipped configuration. Vav, bone marrow or spleen from VavCre;FF1 mice; Mx, bone marrow or spleen from MxCre;FF1 mice. The percentage of flipped transgenes (% flipped) was determined by quantification of the flipped and native bands on a phosphorimager. Transgene (Tg) copies were determined by real time PCR and the numbers of active copies were calculated by multiplying with the percentage of flipped alleles. (D) Correlation of human/mouse JAK2 mRNA ratio with the number of flipped alleles (left) and correlation of hemoglobin with the human/mouse mRNA ratio (right). MxCre;FF1 mice received 1x, 3x or 6x injections of pIpC and were analyzed at 12 weeks. The number of flipped alleles was determined by real-time PCR, which yielded similar results as Southern blot analysis. VavCre;FF1 mice (age 12 weeks) were included for comparison. For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From
